STOCK TITAN

Vanguard (BLFS) Amendment shows 0 shares and 0% after Jan 12, 2026 realignment

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0%, for BioLife Solutions Inc. The filing states an internal realignment on January 12, 2026 resulted in disaggregated reporting by subsidiaries; the amendment is signed on March 26, 2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after internal realignment.

The filing lists an amount beneficially owned of 0 and Percent of class of 0%. It attributes the reporting change to an internal realignment on January 12, 2026 and disaggregation of subsidiary holdings.

Cash‑flow treatment and any prior holdings are not stated in the excerpt; subsequent filings or registrants may show redistributed positions by specific Vanguard subsidiaries.

Amendment explains reliance on SEC Release No. 34-39538 for disaggregated reporting.

The text cites SEC Release No. 34-39538 (January 12, 1998) as the basis for separate reporting by Vanguard subsidiaries. The filing clarifies that The Vanguard Group, Inc. "no longer has, or is deemed to have, beneficial ownership" over securities held by those units.

Investors should note this is a reporting/attribution change; the excerpt does not state transactions or changes in aggregate shareholder ownership levels.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report in the Schedule 13G/A for BLFS?

Vanguard reports 0 shares of Common Stock, representing 0% of the class. The amendment attributes this to an internal realignment and disaggregated reporting by Vanguard subsidiaries effective January 12, 2026.

Does the filing indicate Vanguard sold BLFS shares?

No; the filing does not state any sale or purchase. It explains an internal realignment and separate subsidiary reporting in reliance on SEC Release No. 34-39538, without describing transaction activity or cash flows.

When did Vanguard's internal realignment occur for the BLFS filing?

The filing states the internal realignment occurred on January 12, 2026. The amendment is signed on March 26, 2026, reflecting the disaggregated reporting thereafter.

Who signed the Schedule 13G/A amendment for BLFS?

The amendment is signed by Ashley Grim, Head of Global Fund Administration. The signature date shown in the excerpt is March 26, 2026.

Does the filing show any Vanguard subsidiary holdings in BLFS?

The excerpt does not list subsidiary holdings or amounts. It states certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538, without disclosing their specific balances.
Biolife Solutions Inc

NASDAQ:BLFS

View BLFS Stock Overview

BLFS Rankings

BLFS Latest News

BLFS Latest SEC Filings

BLFS Stock Data

959.24M
46.93M
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States
BOTHELL